Cancers, Vol. 11, Pages 1320: Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer

Cancers, Vol. 11, Pages 1320: Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer Cancers doi: 10.3390/cancers11091320 Authors: Nazareth Jones Gabrielli The poor selectivity of standard cytotoxic chemotherapy regimens causes severe side-effects in patients and reduces the quality of life during treatment. Targeting cancer-specific vulnerabilities can improve response rates, increase overall survival and limit toxic side effects in patients. Oncogene-induced replication stress serves as a tumour specific vulnerability and rationale for the clinical development of inhibitors targeting the DNA damage response (DDR) kinases (CHK1, ATR, ATM and WEE1). CHK1 inhibitors (CHK1i) have served as the pilot compounds in this class and their efficacy in clinical trials as single agents has been disappointing. Initial attempts to combine CHK1i with chemotherapies agents that enhance replication stress (such as gemcitabine) were reported to be excessively toxic. More recently, it has emerged that combining CHK1i with subclinical doses of replication stress inducers is more effective, better tolerated and more compatible with immunotherapies. Here we focus on the lessons learned during the clinical development of CHK1i with the goal of improving the design of future clinical trials utilizing DDR inhibitors to target replication stress in cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research